The Cooper Companies Reports 7.9% Increase in Net Sales but Faces $77.9 Million Net Loss in Q2 2026

The Cooper Companies, Inc. reported a significant increase in net sales for the second quarter of fiscal 2026, reaching $1,081.5 million, up from $1,002.3 million in the same period last year, marking an increase of 7.9%. For the first half of the fiscal year, net sales totaled $2,105.6 million, compared to $1,967.0 million in the prior year, reflecting a growth of 7.0%. However, the company experienced a net loss of $77.9 million for the quarter, a stark contrast to the net income of $87.7 million reported in the same quarter of 2025. This resulted in a loss per share of $0.40, compared to earnings of $0.44 per share in the previous year.

The financial performance was notably impacted by a $271.6 million litigation expense related to ongoing legal matters, which significantly affected the company's profitability. Selling, general, and administrative expenses surged to $676.2 million for the quarter, up from $399.0 million in the prior year, primarily due to this litigation expense. Research and development expenses remained relatively stable, totaling $42.5 million for the quarter, down slightly from $45.5 million in the previous year. The company’s gross profit for the quarter was $735.4 million, yielding a gross margin of 68%, consistent with the previous year.

In terms of operational developments, CooperVision, one of the company's segments, reported net sales of $723.5 million for the quarter, an increase of 8.1% from $669.6 million in the prior year. The growth was driven by strong sales in toric and multifocal lenses, which saw an 11% increase, and spherical lenses, which grew by 5%. CooperSurgical also contributed to the overall sales growth, with net sales of $358.0 million, up 7.6% from $332.7 million in the same quarter last year. The company continues to expand its market presence, particularly in the Americas and EMEA regions, although sales in the Asia Pacific region declined by 6%.

The company’s balance sheet as of April 30, 2026, showed total assets of $12.48 billion, a slight increase from $12.39 billion at the end of the previous fiscal year. Current liabilities rose significantly to $1.80 billion, primarily due to an increase in short-term debt, which reached $598.9 million compared to $47.8 million at the end of October 2025. The company’s cash and cash equivalents also increased to $138.8 million from $110.6 million. Looking ahead, Cooper Companies expressed optimism about long-term growth prospects in the contact lens and healthcare markets, despite facing significant risks and uncertainties, including macroeconomic conditions and ongoing litigation. The company remains focused on leveraging its product innovations and expanding its market share in both existing and emerging markets.